期刊文献+

纳米金标芯片检测用于前列腺癌多基因诊断的实验研究 被引量:1

Gold Nanoparticles microarray for the diagnosis of prostate cancer experimental study of mutiple genes
下载PDF
导出
摘要 目的利用纳米金标基因芯片检测前列腺癌(prostatic cancer,PCa)特异性多基因,探讨其临床意义。方法应用纳米金标基因芯片对11个PCa特异性基因靶标(IGF1、P27、AR、PSMA、KLK3、PCNA、Ki-67、KLK1、KLK2、TMPRSS2、SREBF2)进行检测,对各基因表达进行研究。结果纳米金标基因芯片检测单链核酸的灵敏度达到80f mol/L,在优化条件下,目标上调基因呈阳性表达,下调及阴性对照无显色,可肉眼分辨。结论纳米金标基因芯片技术检测PCa特异性基因方法快速简单,灵敏度高,特异性好,可对选定的11个目标基因定性及半定量检测,不需要借助于特殊仪器,操作简单,样本保存时间长,在普通实验室即可完成。纳米金标基因芯片检测有望成为PCa早期诊断的新一代芯片检测系统。 Objective To detect multiple genes of the prostatic cancer with labelled Nanogold microarray and deal with its clinical significance.Methods Application of the labelled Nanogold microarray to detect 11 kinds of genes for prostate cancer targets(IGF1,P27,AR,PSMA,KLK3,PCNA,Ki-67,KLK1,KLK2,TMPRSS2,SREBF2),study on each of the gene expressions.Results The sensitivity of dectection of the single-stranded DNA with the method of labelled Nanogold microarray reached to 80 fmol/L,under the condition of optimised,each upregulation gene probe point presented the obvious chromogenic expression.Downregulation gene and the negative control presented no chromogenic expression.This can be identified by naked eyes.Conclusions Utilize the labelled Nanogold microarray to detect multiple genes of the prostatic cancer is simple.It has a high sensitivity and a high specificity.It can achieve a qualitative or semi-quatitative detection without the help of any special instruments for the 11 kinds of genes for prostate cancer targets we has choose.Also,the procedure is easy,which can be done in a normal laboratory,and the sample can be preserved for a long time.So it is expected to be a new generation of the chip detection system on early diagnosis of the prostatic cancer.
出处 《现代泌尿生殖肿瘤杂志》 2011年第1期22-25,共4页 Journal of Contemporary Urologic and Reproductive Oncology
基金 国家高科技863重点项目(2006AA02A245 2007AA022001) 国家自然科学基金项目(30872960) 广东省自然科学基金项目(04003650) 广州市卫生局重点项目(2007-Zdi-05)
关键词 前列腺肿瘤 纳米技术 芯片分析技术 基因表达 Prostatic neoplasms Nanotechnology Microchip analytical procedures Gene expression
  • 相关文献

参考文献17

  • 1叶定伟,朱耀.中国前列腺癌的发病趋势[M]//马军.中国临床肿瘤学教育专辑.哈尔滨:黑龙江科学技术出版社,2007:616-620.
  • 2钟惟德,何慧婵,刘良式,刘文华,江福能,魏鸿蔼.应用基因芯片诊断前列腺癌的初步研究[J].中华医学杂志,2004,84(7):564-565. 被引量:3
  • 3Paliouras M, Borgono C, Diamandis EP. Human tissue kal- likreins: The cancer blomarker family[J]. Cancer Lett, 2007, 249(1):61-79.
  • 4Yousef OM,Diamandis EP. The new human tissue kallikreirl gene family: structure, function, and association to disease [J]. Endocr Rev,2001,22(2) : 184-204.
  • 5Diamandis EP,Yousef GM. Human tissue kallikrein:a family of new cancer biomarkers[J]. Clin Chem,2002,48(8) :1198-1205.
  • 6Scorilas A, Gregorakis AK. mRNA expression analysis of hu- man kallikrein 11 (KLK11) may be useful in the discrimina- tion of benign prostatic hyperplasia from prostate cancer after needle prostate biopsy[J]. Biol Chem, 2006,387 (6) : 789-793.
  • 7Nakamura T, Stephan C, Scorilas A, et al. Quantitative a- nalysis of hippostasin/KI.Kll gene expression in cancerous and noncancerous prostatic tissues[J]. Urology, 2003,61 ( 5 ):. 1042-1046.
  • 8Gerdes J, Schwab U, Lemke H, et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation [J]. Int J Cancer, 1983,31 (1) .-13-20.
  • 9Gharpin C, Dicaire MJ, Barbeau B, et al. Monoclonal 3C6F dis- tribution in human breast carcinomas:image cytometry of im- munocytochemical assays[J]. Med Oncol Tumor Pharmaco- ther, 1991,8(4) :243-251.
  • 10刘喜波,孟春琴.Ki-67和CK34βE12在前列腺癌鉴别诊断中的应用[J].肿瘤研究与临床,2005,17(3):187-188. 被引量:5

二级参考文献31

  • 1Thomas H,Nasin MM,Sarraf CE, et al.PCNA immunostaining:a prognostic factor in ovarian cancer[J]? Br J Cancer, 1995,71:357.
  • 2Harris AL. Mutant P53-the commonest abnormality in human cancer[J]. J Pathol, 1990,329: 219.
  • 3Levine AJ,Momand J,Finlay CA.The P53 tumor suppressor gene[J].Natuze, 1991,351:453 ~ 457.
  • 4Heidenberg H, Bauer J, Mcleod D, et al. The role of the P53 tumor suppressor gene in prostate cancer: a possible biomarker[J] ? Urology, 1996,48:971 ~ 979.
  • 5Celis JE, et al. Cell-dependent variations in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultural cells:subdivision of S phase[J] .Proc Natl Acad Sci USA, 1985,82:3262.
  • 6Yamanaka S, Nagai N, Ohaka A. Study of proliferative cell nuclear antigen (PCNA), nuclear organizer regions(NORS) and mitotic activity in epithelial ovarian tumors [J]. Nippon Sanka Fujinka Gakkai Zasshi, 1993, 45(3) :234.
  • 7Jussila T,Stenback F.Cell proliferation markers and growth factors in overian cancer[J]. Ann Med, 1995,27 (1): 87.
  • 8Van Dierendonck JH, Wijsman JH, Keijzer R, et al. Cellcycle-related staining patterns of anti-proliferating cell nuclear antigen monoclonal antibodies,comparison with BUdR labeling and ki-67 staining [J]. Am J Pathol, 1991,138(5): 1165.
  • 9Devaraj L T, Bostwick D G. Atypical basal cell hyperplasia of the prostate. Immunophenotypic profile and proposed classification of basal cell proliferations[J]. Am J Surg Pathol, 1993, 17(7):645-659.
  • 10Wojno K J, Epstein J I. The utility of basal cell-specific anti-cytokeratin antibody (34 beta E12) in the diagnosis of prostate cancer. A review of 228 cases[J]. Am J Surg Pathol, 1995, 19(3):251-260.

共引文献17

同被引文献13

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部